U.S. ibogaine & noribogaine research
A careful chronological view of the U.S. research pathway: preclinical work, early clinical development, public funding signals, and the important distance between an investigational program and an approved medicine.
How to read this record
Ibogaine remains a Schedule I controlled substance in the United States. That legal status shapes the research route: laboratory work, protocol development, regulatory review, and carefully controlled studies are different things from routine medical availability. The DEA’s drug-scheduling framework is one useful starting point for that distinction.
This page focuses on U.S.-based scientific and regulatory activity. It does not treat overseas treatment centers as U.S. clinical trials, and it does not turn announcements, grants, or planned studies into evidence of benefit. For the broader orientation that frames this timeline, visit the site’s U.S. ibogaine research overview.
Preclinical work generally refers to research outside human efficacy trials. A Phase 1 study usually emphasizes safety, tolerability, or pharmacokinetics. Phase 2 work commonly examines preliminary clinical signals alongside safety. These labels describe study stages, not approval.
Early scientific foundations
U.S. and international investigators examined ibogaine and its metabolite noribogaine in laboratory and animal research, including questions about receptor activity, metabolism, and behavioral models related to substance use. A useful broad reference point is the historical overview of ibogaine, although primary papers remain more appropriate for specific findings.
Noribogaine, a principal metabolite of ibogaine, has drawn separate interest because development programs can investigate it as a distinct investigational compound. That distinction matters: a noribogaine program is not the same as an ibogaine program, and neither establishes routine clinical use.
Published concern about cardiac effects, including QT-interval prolongation, has made screening, monitoring, and dose design central scientific questions rather than administrative details. The U.S. Food and Drug Administration’s drug-development safety information provides context for why interaction and metabolism questions matter in investigational programs.
Human research pathway
In the United States, a sponsor seeking to administer an investigational drug in a clinical study generally works through the Investigational New Drug process. The FDA explains that an Investigational New Drug application is the mechanism through which a proposed human study may proceed when the required conditions are met. It is not a marketing authorization.
Public registries are particularly important for separating an announced plan from a listed study. A record on the federal clinical-study registry can identify a protocol’s status, study type, endpoint descriptions, sponsor, locations, and eligibility language when those details are posted. Registry entries can change, so their timestamps and current recruitment status should be read carefully.
Federal signals
Recent public attention has included research-oriented notices and announcements involving agencies such as the National Institutes of Health, the Department of Defense, and the Department of Veterans Affairs. A funding opportunity or research initiative can signal that a question is being examined; it does not mean that a product has demonstrated efficacy, safety, or FDA approval.
The National Institutes of Health maintains a public record of its research mission and funding ecosystem, while the Department of Veterans Affairs describes its own health and research context. Individual awards, protocols, and results require separate verification through their underlying notices, registry records, or publications.
“A planned trial, an IND, a grant notice, and an FDA-approved indication are four different milestones.”
When a study names a U.S. site, that location belongs to the protocol as listed. It should not be generalized into national availability, and it does not convert a research site into a public treatment option.
Current landscape
Companies may announce IND clearances, plans for Phase 1 work, or intended development paths for ibogaine-derived or noribogaine-related compounds. The careful next step is to locate the underlying registry record, protocol, regulatory statement, or peer-reviewed publication. An announcement alone does not reveal all endpoints, exclusion criteria, adverse events, or final results.
Academic studies and investigator-initiated research can answer narrow questions about feasibility, safety, monitoring, or outcome measurement. The guide to reading trial pathways explains why a listed study’s design and status matter more than a headline about it.
Key uncertainties include who can safely participate, how cardiac risks can be characterized and managed, how long any observed outcomes last, and whether findings from small or early studies translate to broader populations. These are research questions, not grounds for treatment advice. The site’s safety and legal context keeps those questions in view.
Common distinctions
Terminology is often used loosely in public discussion. These short answers preserve the boundaries between research activity, clinical access, and regulatory status.
No. An IND can permit a sponsor to study a product in people under an investigational framework. It does not establish that the product is FDA approved for routine treatment, and it does not settle benefit-risk questions.
No. Treatment centers outside the United States are distinct from U.S.-based, registered clinical research. Their services, legal environment, and monitoring practices should not be represented as U.S. trial evidence.
Where available, look for the registry identifier, sponsor, study phase or type, primary endpoints, listed locations, recruitment status, and completion dates. A result publication may answer different questions than a registry listing.
They are related but not interchangeable in a development program. Study design, dose, pharmacology, endpoints, and regulatory documentation may differ. For the site’s purpose and principles, see the resource’s approach to evidence and uncertainty.
Keep the categories separate
This timeline is designed to help readers distinguish preclinical signals, registered studies, funding activity, and regulatory steps from established medical use.